CDX-301 will be the good fairy godmother that will be the multudinous collaborator!
"...multiple opportunities for clinical development of this program, including cancer therapy, in vivo and ex vivo expansion of dendritic cells for cancer immunotherapy, radiation countermeasures and burn management."
It would be nice to hear something from management during the quarterly conference call about progress concerning possible partnerships. Yes, CLDX has sufficient cash to fund operations through the end of next year, but a year passes quickly and cash is being depleted without a source of revenue. I wonder whether partnerships or another secondary share offering will be the more likely source of additional funds looking into next year.
If CLDX hits $30 per share by the end of this year and sustains that growth on good news by hitting $40 in the first quarter or half of 2014, I believe management would consider selling an additional 3-4 million shares to be an attractive option to raise another $100-$150 million to fund operations well into the approval and marketing of both 110 and 011, at which point CLDX would still own its own pipeline entirely and have a revenue stream to boot.
Whipper, you are on target with your thinking, and I think that may be what other investors think may happen before years end at around current prices. It would be the best thing IMO, and should catapult this stock to $30 plus in a relative short time. Without raising more cash, the uncertainty will hang over Celldex and slow its progression. But who really knows.
Remember, raise funds when you can, not when you need.